Brunswick Group is counseling China's Simcere Pharmaceuticals as the New York Stock Exchange-traded cancer and heart disease drug developer weighs a plan to become the latest Chinese company to exit a public listing.

Full Story | Subscribe to O'Dwyer's | Free E-Newsletter on PR